The total return over the past 12 months is -15.59% vs. +16.94% for the S&P 500. So far it's up -48.07% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (15.59%) | +0.89% | (23.91%) | (11.90%) | (1.07%) | (3.64%) |
| Total Return CAGR | (15.59%) | +0.89% | (23.91%) | (11.90%) | (1.07%) | (3.64%) |
| Revenue CAGR | +6.02% | +0.66% | (3.56%) | +5.24% | +14.07% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Vanda Pharmaceuticals Inc. (VNDA)
| Year | Start price | End price | VNDA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.82 | $4.58 | (48.07%) | +14.51% | (62.58%) |
| 2025 | $4.79 | $8.82 | +84.13% | +17.72% | +66.41% |
| 2024 | $4.22 | $4.79 | +13.51% | +24.89% | (11.38%) |
| 2023 | $7.39 | $4.22 | (42.90%) | +26.19% | (69.09%) |
| 2022 | $15.69 | $7.39 | (52.90%) | (18.17%) | (34.73%) |
| 2021 | $13.14 | $15.69 | +19.41% | +28.74% | (9.33%) |
| 2020 | $16.41 | $13.14 | (19.93%) | +18.37% | (38.30%) |
| 2019 | $26.13 | $16.41 | (37.20%) | +31.22% | (68.42%) |
| 2018 | $15.20 | $26.13 | +71.91% | (4.56%) | +76.47% |
| 2017 | $15.95 | $15.20 | (4.70%) | +21.70% | (26.40%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
